Back to results
US 12,227,577 B2Granted
Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer
AssigneeMerck Patent GmbH
InventorsMarat Alimzhanov, Patricia Soulard, Frank Zenke, Heike Dahmen, Astrid Zimmermann, Andreas Schroeder, Keyvan Tadjalli Mehr, Martin Falk
Life of this patent
Estimating the term…
Abstract
The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to a therapeutic combination which comprises a PD-1 antagonist, an ATR inhibitor and a platinating agent.
Claims10
A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a PD-1 antagonist, an ATR inhibitor and a platinating agent,
- wherein the PD-1 antagonist is selected from the group consisting of avelumab, nivolumab, pembrolizumab, atezolizumab, durvalumab and cemiplimab, and
- wherein the ATR inhibitor is selected from the group consisting of Compound 1, or a pharmaceutically acceptable salt thereof, Compound 2, or a pharmaceutically acceptable salt thereof, Compound 3, or a pharmaceutically acceptable salt thereof, Compound 4, or a pharmaceutically acceptable salt thereof, and Compound 5, or a pharmaceutically acceptable salt thereof.
A kit comprising a PD-1 antagonist, an ATR inhibitor and a platinating agent,
- wherein the PD-1 antagonist is selected from the group consisting of avelumab, nivolumab, pembrolizumab, atezolizumab, durvalumab and cemiplimab, and
- wherein the ATR inhibitor is selected from the group consisting of Compound 1, or a pharmaceutically acceptable salt thereof, Compound 2, or a pharmaceutically acceptable salt thereof, Compound 3, or a pharmaceutically acceptable salt thereof, Compound 4, or a pharmaceutically acceptable salt thereof, and Compound 5, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.